MP CARDIOFLOW-B (02160) issues a profit warning, expecting a mid-term net loss of no more than $25 million.

MP CARDIOFLOW-B (02160) announced that, as the Group completed the acquisition of the cardiac rhythm management (CRM) business on December 19, 2025 (the Acquisition Transaction), the CRM business will be fully consolidated into the Group's financial statements for the first six months ending June 30, 2026 (the Reporting Period). Based on the preliminary review of the Group's unaudited consolidated management accounts for the Reporting Period and the assessment of the latest information currently available to the Board, the Group expects to record revenue of not less than USD 153 million and a net loss of not more than USD 25 million for the Reporting Period. During the Reporting Period, the Group's global cardiac rhythm management business continued to grow steadily, particularly with a double-digit increase in the number of pacemakers implanted in the Chinese market. At the same time, leveraging the mature channels and resources in global registration and commercialization of the CRM business, the companys VitaFlow Liberty transcatheter aortic valve replacement system has accelerated its commercialization in CE certification-covered areas, with registration and sales in emerging countries ramping up concurrently, achieving over 350% growth in implantations across more than 40 countries outside China compared to the six-month period ending June 30, 2025, and setting a record of over 250 implants in a single month. Furthermore, since the completion of the Acquisition Transaction, the Group has been implementing a series of integration measures to continuously release synergistic effects and has been deepening cost control initiatives to further enhance operational efficiency and reduce operational costs.